Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Infectious diseases gene therapy

In sum, RNAi clearly has the potential to change the nucleic-based therapies for cancer, infectious diseases, and many other diseases. However, the universality of this approach, the types of genes that can be silenced using these strategies in human cells, remain unknown to date. [Pg.1093]

To date, cellular and gene therapy products submitted to FDA have included clinical studies indicated for bone marrow marking, cancer, cystic fibrosis, AIDS, and inborn errors of metabolism and infectious diseases. Of the current active INDs approximately 78% have been sponsored by individual investigators or academic institutions and 22% have also been industry sponsored. In addition to the variety of clinical indications the cell types have also been varied. Examples include tumor infiltrating lymphocytes (TIL) and lymphocyte activated killer (LAK) cells, selected cells from bone marrow and peripheral blood lymphocytes, for example, stem cells, myoblasts, tumor cells and encapsulated cells (e.g., islet cells and adrenal chromaffin cells). [Pg.65]

The potential use of gene therapy has since expanded as conditions such as cancer, atherosclerosis, transplant operations, and infectious disease are now viewed as suitable targets for intervention. For example, HTV and parasitic infection (2-5). Furthermore, the ability to transfer genes into cell in vitro is also an important tool in the research of gene expression. [Pg.294]

Rondon, I.J., and W.A. Marasco. 1997. Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. [Pg.91]

Alveoli represent the primary site for gas exchange within the lung, and thus their health is vital for survival. Alveolar conditions with a primary genetic cause, such as surfactant protein-B (SP-B) deficiency and SP-C deficiency, are prime candidates for a rAAV-gene therapy approach. Diseases in which alveoli are damaged secondary to other defects might also be treated with gene transfer. Such conditions include environmental toxin exposure, infectious diseases, and adult respiratory distress syndrome (ARDS) (Table 4.1) (Rolls et al., 1997, 1998, 2001 Cheers et al 1999 Ruan et al., 2002). [Pg.85]

Brunnell A, Morgan R (1998), Gene therapy for infectious diseases, Clin. Microbiol. Rev. 11 42-56. [Pg.503]

Pulmonary delivery of liposomes has focused on the treatment of asthma, infectious diseases, genetic diseases (cystic fibrosis), and lung injury and lately on gene therapy. [Pg.473]

Table 5 Infectious disease phase I and II ongoing gene therapy clinical trials as of February 1, 2001... Table 5 Infectious disease phase I and II ongoing gene therapy clinical trials as of February 1, 2001...
Profile Founded in May 1981, Chiron is a 1 + billion science-driven healthcare company that combines diagnostic, vaccine, and therapeutic strategies for controlling disease. The company has research programs in gene therapy, combinatorial chemistry, cancer, infectious and cardiovascular disease, and critical care through its Chiron Technologies business unit. [Pg.239]


See other pages where Infectious diseases gene therapy is mentioned: [Pg.50]    [Pg.434]    [Pg.194]    [Pg.249]    [Pg.22]    [Pg.420]    [Pg.444]    [Pg.617]    [Pg.131]    [Pg.13]    [Pg.463]    [Pg.486]    [Pg.172]    [Pg.573]    [Pg.229]    [Pg.234]    [Pg.36]    [Pg.258]    [Pg.356]    [Pg.52]    [Pg.319]    [Pg.58]    [Pg.121]    [Pg.87]    [Pg.410]    [Pg.489]    [Pg.498]    [Pg.502]    [Pg.351]    [Pg.670]    [Pg.716]    [Pg.239]    [Pg.14]    [Pg.8]    [Pg.8]    [Pg.278]    [Pg.1426]    [Pg.576]    [Pg.18]    [Pg.125]   
See also in sourсe #XX -- [ Pg.43 ]




SEARCH



Disease genes

Disease therapy

Gene disease genes

Gene therapy

Gene therapy infectious disease, clinical trials

Infectious

Infectious diseases

© 2024 chempedia.info